Navigation Links
Genomic Health Announces Results from Two Studies Demonstrating Innovations in Next Generation Sequencing From Paraffin Tissue, Enhancing Understanding of Tumor Biology
Date:2/25/2013

c Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional treatment decisions in breast and colon cancers.  The company is based in Redwood City, California with European headquarters in Geneva, Switzerland.  For more information, please visit, www.GenomicHealth.com. To learn more about Oncotype DX tests, visit: www.OncotypeDX.com and www.mybreastcancertreatment.org

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to our ability to generate similar results in further studies, the clinical utility of our next generation sequencing capabilities; our ability to develop whole transcriptome and/or genome expression analysis for routine clinical study; the belief that whole genome expression may accelerate clinical or biomarker discovery; our ability to develop, validate or commercialize advanced diagnostics based upon such genome expression data; the timing of such studies and results;  the company's ability to accelerate its research and development efforts to move whole genome expression technology into clinical studies and; the company's ability to obtain intellectual property protection for such discoveries. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. The
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Convey Hybrid-core to Speed Genomic Research at Broad Institute
2. Real Time Genomics® Announces Platform Launch, Expanding Commercial Operations
3. TopCoders Open Community Challenge Process Yields 970 Fold Increase in Speed for Big Data Genomics Sequencing Algorithm
4. DNA Genotek Inc. Announces $10,000 GenoFIND™ Genomic Services Award
5. Genomic Health Announces Presentation of Six Studies at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium
6. Boston Childrens Hospital announces international genomics competition winner
7. Law Office of Brodsky & Smith, LLC Announces Investigation of Complete Genomics, Inc.
8. Genomic Health Announces Positive Topline Results of Large Prostate Cancer Clinical Validation Study; Company to Proceed with 2013 Commercial Launch
9. Synthetic Genomics Inc. Purchases Patent Portfolio from Febit Holding GmbH
10. Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics: Twease.org
11. Rosetta Genomics Expands Management Team, Laboratory Capacities and Commercial Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015  Two years after its ... hackers and citizen scientists, Oakland -based ... campaign promoting its mission to democratize science through a ... Photo ... Based out of the new ...
(Date:5/27/2015)... 2015 ­ Caris Life Sciences®, a leading ... medicine, today announced it has appointed the Levine Cancer ... excellence site in the Caris Centers of Excellence for ... Institute is one of the largest cancer care providers ... cancer patients annually. Derek Raghavan , M.D., Ph.D., ...
(Date:5/26/2015)... , Kalifornien und HILDEN, Deutschland, May 26, ... Clinical Insight ®   ... und die Erstellung dazugehöriger Berichte; Vorstellung auf ... QIAGEN N.V. (NASDAQ: QGEN ... die Markteinführung von QIAGEN Clinical Insight ® ...
(Date:5/26/2015)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ), ... modernized traditional Chinese medicine (mTCM), branded generics and active ... of Shareholders for fiscal year ended June 30, 2014 ... office located in Chengdu, China ... in Chengdu, China ) on May ...
Breaking Biology Technology:East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 2East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 2Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 3
... Supply Chain Circassia to Develop Dopexamine as Part of ... ... OXFORD, England, October 8 Circassia Ltd, a specialty,biopharmaceutical ... today that it has acquired the US, Canadian and Japanese,development ...
... by allowing for the rapid ... of molecules using a single reaction, ST. LOUIS, ... that it has signed an exclusive licensing,agreement with the ... quantities of powerful new boronic acid,surrogates for use in ...
... for Landmark ApoA-I Trial, TSX Exchange Symbol: ... Corp.,("Resverlogix" or the "Company") (TSX:RVX) is pleased to ... RVX-208 Phase 2b clinical trial,assessing atherosclerosis by IVUS ... Syndrome patients expected to start in 2009., ...
Cached Biology Technology:Circassia Acquires North American and Japanese Rights to Dopexamine 2Circassia Acquires North American and Japanese Rights to Dopexamine 3Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement 2Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement 3International Steering Committee for RVX-208 IVUS Trial Formed 2International Steering Committee for RVX-208 IVUS Trial Formed 3
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... is available in German . During the ... humans, chromosomes are broken and rearranged at many positions. Using ... Klein, professor for genetics at the Max F. Perutz Laboratories ... high resolution. The surprising observations regarding the mechanism of meiosis ...
... part of human history for well over 30,000 years, used ... paint. Now, researchers from the Perelman School of Medicine ... have a new use for the 21st century: protecting healthy ... In a study just published in BMC Cancer , ...
... Total joint replacement surgeries can help relieve joint ... But sometimes, the debris from prosthetic joints leads ... In 2009, a Wayne State University researcher determined ... treat such disintegration. There was one caveat, however: ...
Cached Biology News:The machinery for recombination is part of the chromosome structure 2The machinery for recombination is part of the chromosome structure 3Penn study shows an ancient crop effective in protecting against a 21st century hazard 2Penn study shows an ancient crop effective in protecting against a 21st century hazard 3Wayne State researcher discovers antibiotic useful for localized treatment of bone wear 2
Mouse polyclonal antibody to BAG2 - BCL2-associated athanogene 2...
96-well format (For processing samples on microplate-size MALDI target plates such as those from Bruker, Shimadzu, Thermo, and PerkinElmer) Packaging: 2 / pack...
... antibody raised against a partial recombinant IFNA2. ... partial recombinant protein is produced in E. coli. ... IU/ mg. OMIM: 147562, ... Lot Number: MM951100564 MA Code: ...
Mouse monoclonal antibody raised against a partial recombinant CENTB2. NCBI Entrez Gene ID = CENTB2...
Biology Products: